Frederick Zeleznik
About Frederick Zeleznik
Frederick Zeleznik is the Executive Director of U.S. Value, Access, and Payment Strategy at Bristol-Myers Squibb, with over 15 years of experience in various leadership roles within the company.
Title
Frederick Zeleznik currently serves as the Executive Director for U.S. Value, Access, and Payment Strategy at Bristol-Myers Squibb, based in New Jersey, United States.
Current Role at Bristol-Myers Squibb
Frederick Zeleznik leads the U.S. Value, Access, and Payment Strategy as the Executive Director at Bristol-Myers Squibb. He is responsible for developing and implementing strategies to enhance the value and accessibility of the company's pharmaceutical offerings in the United States.
Previous Roles at Bristol-Myers Squibb
Frederick Zeleznik has held various leadership positions within Bristol-Myers Squibb over a 15-year period. His previous roles include: Director for U.S. Oncology Value and Access (2016-2019), Director for Market Access Strategy in Immunology and Oncology (2013-2016), Senior Manager for Eliquis Marketing (2010-2013), Senior Manager for Avapro and Avalide Marketing (2008-2010), Associate Director for Access Contracting Strategy and Execution (2006-2008), and Associate Director for U.S. Pricing and Economics (2004-2006).
Education and Expertise
Frederick Zeleznik holds a Master of Business Administration with a focus on Financial Management from Drexel University's LeBow College of Business. He earned a Bachelor of Science in Economics from Penn State University. His educational background equips him with strong expertise in financial analysis, market access strategy, and economic modeling within the pharmaceutical industry.
Experience at Pfizer
Before joining Bristol-Myers Squibb, Frederick Zeleznik worked at Pfizer as a Manager of Financial Analysis and Control for the Global Prescription Business from 2001 to 2003, based in New York, New York. In this role, he was responsible for conducting financial analyses and implementing controls to support the company's global prescription initiatives.